We are live on
!
Find out more
Madrigal Pharmaceuticals
MDGL
MDGL
91 hedge funds and large institutions have $471M invested in Madrigal Pharmaceuticals in 2017 Q4 according to their latest regulatory filings, with 46 funds opening new positions, 25 increasing their positions, 10 reducing their positions, and 8 closing their positions.
New
Increased
Maintained
Reduced
Closed
475% more first-time investments, than exits
New positions opened: 46 | Existing positions closed: 8
291% more capital invested
Capital invested by funds: $120M → $471M (+$350M)
150% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 10
72% more funds holding
Funds holding: 53 → 91 (+38)
15.11% more ownership
Funds ownership: 21.39% → 36.5% (+15%)
Holders
91
Holders Change
+38
Holders Change %
+71.7%
% of All Funds
2.06%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
46
Increased
25
Reduced
10
Closed
8
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–
Top Buyers
| 1 |
BBA
Baker Bros. Advisors
New York
|
+$31.9M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$21.8M |
| 3 |
Jennison Associates
New York
|
+$11.7M |
| 4 |
PA
Perceptive Advisors
New York
|
+$10.8M |
| 5 |
PC
Polar Capital
London,
United Kingdom
|
+$10.3M |
Top Sellers
| 1 |
AC
Armistice Capital
New York
|
-$8.68M |
| 2 |
FCMI
Foresite Capital Management III
Larkspur,
California
|
-$4.5M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
-$2.77M |
| 4 |
Renaissance Technologies
New York
|
-$2.27M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$1.64M |
